Catalyst Wire Dossier Catalyst Wire Dossier

MK-0000-222

· Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-0000-222, covering 2013-07-08 to 2013-07-08. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222) [Phase 1]

See pricing